Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients With Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma

NCT05038644 is registered in ClinicalTrials.gov with Ehab L Atallah as lead sponsor.

NCT NCT05038644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05038644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MCW-XEN21: A Phase 1 Study of XmAb18968 (CD3-CD38) for the Treatment of Patients With Relapsed/Refractory CD38 Positive Acute Leukemia and T Cell Lymphoblastic Lymphoma
Lead sponsor
Ehab L Atallah
Phase
Phase 1
Overall status
Terminated
Start date
February 2, 2022
Completion date
November 18, 2024
Enrollment
22 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, t cell acute lymphoblastic leukemia, t cell lymphoblastic lymphoma